Clinical trials
Enrolling by invitation Observational trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
256 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 7 |
| 2021 | 13 |
| 2022 | 7 |
| 2023 | 28 |
| 2024 | 66 |
| 2025 | 79 |
| 2026 | 37 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Enrolling by invitation | 256 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 9 |
| Peking University Third Hospital | 9 |
| Nanfang Hospital, Southern Medical University | 6 |
| The First Affiliated Hospital with Nanjing Medical University | 6 |
| Beijing Chao Yang Hospital | 5 |
| Fudan University | 5 |
| Ruijin Hospital | 5 |
| Shanghai Chest Hospital | 4 |
| Tongji Hospital | 4 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Stomach Neoplasms | 8 |
| Breast Neoplasms | 7 |
| Carcinoma, Hepatocellular | 6 |
| Carcinoma, Non-Small-Cell Lung | 6 |
| Heart Failure | 6 |
| Cognitive Dysfunction | 5 |
| Disease | 5 |
| Neoplasms | 5 |
| Cardiovascular Diseases | 4 |
| Sepsis | 4 |
Trials
Showing 1 to 25 of 256. Each trial links to its page on Pharma Observatory.
156 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.